Klf4-Tymp axis promotes inflammation-driven early tumorigenesis by enhancing kras mutation-induced acinar-to-ductal metaplasia through Pi3k/Akt and Mek/Erk pathways.
Qihang Yuan, Junhong Chen, Peng Luo, Kai Liu, Fangyue Guo, Yao Xu, Mengying Tong, Hong Xiang, Dong Shang
{"title":"Klf4-Tymp axis promotes inflammation-driven early tumorigenesis by enhancing kras mutation-induced acinar-to-ductal metaplasia through Pi3k/Akt and Mek/Erk pathways.","authors":"Qihang Yuan, Junhong Chen, Peng Luo, Kai Liu, Fangyue Guo, Yao Xu, Mengying Tong, Hong Xiang, Dong Shang","doi":"10.1186/s13046-026-03712-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Acinar-to-ductal metaplasia (ADM) is a pivotal step in pancreatic tumorigenesis, reversible in normal contexts but progressing to PanIN and pancreatic cancer (PC) in the presence of Kras mutation and inflammation. Thus, delineating exocrine cell heterogeneity and identifying regulators of ADM are essential for understanding pancreatic tumorigenesis.</p><p><strong>Methods: </strong>We collected single-cell RNA sequencing (scRNA-seq) data of 146 human pancreatic samples, followed by comprehensive exploration of dynamic change and heterogeneity of ADM via machine learning algorithms. Multi-omics analysis integrating ATAC-seq and RNA-seq highlights the association of Klf4-Tymp axis with ADM. A dual-luciferase reporter assay was performed to evaluate the transcriptional activation of the Tymp promoter by Klf4. AAV-mediated gene silencing was performed in vivo to elucidate the roles and underlying mechanisms of the Klf4/Tymp axis during the ADM process in Pdx1-Cre; Kras<sup>G12D/+</sup> (KC) mice. In-vitro mouse pancreatic organoid model combined with amino acid mutation was established to investigate the role of Tymp in regulating ADM and its underlying mechanisms.</p><p><strong>Results: </strong>scRNA-seq revealed one S100A4<sup>+</sup> acinar subpopulation and six ductal subpopulations (GPX1<sup>+</sup>, CD24<sup>+</sup>, TFF3<sup>+</sup>, MT-ATP8<sup>+</sup>, S100A9<sup>+</sup>, and HMGB2<sup>+</sup>) associated with poor prognosis in PC. Integrated pseudotime analysis of pancreatic acinar and ductal cells highlighted the potential involvement of TYMP in regulating the pathological process of ADM. Klf4 was identified as an upstream transcription factor regulating the Tymp gene. ATAC-seq revealed increased chromatin accessibility at the Klf4 and Tymp locus under inflammatory injury or oncogenic Kras conditions. Dual-luciferase reporter assays demonstrated that the transcription factor Klf4 binds to the promoter region of Tymp, thereby promoting its transcriptional expression. Pancreatic overexpression of Klf4 in mice upregulated Tymp expression and facilitated inflammation-induced initiation and progression of ADM. Exogenous supplementation with Tipiracil Hydrochloride suppressed the effects induced by Klf4. Knockdown of the Tymp gene suppressed inflammation-driven initiation and progression of ADM in KC mice through Pi3k/Akt and Mek/Erk pathways.</p><p><strong>Conclusions: </strong>The Klf4-Tymp axis promotes inflammation-associated early pancreatic tumorigenesis by enhancing KRAS mutation-induced ADM through activation of the Pi3k/Akt and Mek/Erk signaling pathways. These findings provide new insights into the molecular mechanisms linking inflammatory injury to ADM and early pancreatic tumorigenesis.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":" ","pages":""},"PeriodicalIF":12.8000,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Experimental & Clinical Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13046-026-03712-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acinar-to-ductal metaplasia (ADM) is a pivotal step in pancreatic tumorigenesis, reversible in normal contexts but progressing to PanIN and pancreatic cancer (PC) in the presence of Kras mutation and inflammation. Thus, delineating exocrine cell heterogeneity and identifying regulators of ADM are essential for understanding pancreatic tumorigenesis.
Methods: We collected single-cell RNA sequencing (scRNA-seq) data of 146 human pancreatic samples, followed by comprehensive exploration of dynamic change and heterogeneity of ADM via machine learning algorithms. Multi-omics analysis integrating ATAC-seq and RNA-seq highlights the association of Klf4-Tymp axis with ADM. A dual-luciferase reporter assay was performed to evaluate the transcriptional activation of the Tymp promoter by Klf4. AAV-mediated gene silencing was performed in vivo to elucidate the roles and underlying mechanisms of the Klf4/Tymp axis during the ADM process in Pdx1-Cre; KrasG12D/+ (KC) mice. In-vitro mouse pancreatic organoid model combined with amino acid mutation was established to investigate the role of Tymp in regulating ADM and its underlying mechanisms.
Results: scRNA-seq revealed one S100A4+ acinar subpopulation and six ductal subpopulations (GPX1+, CD24+, TFF3+, MT-ATP8+, S100A9+, and HMGB2+) associated with poor prognosis in PC. Integrated pseudotime analysis of pancreatic acinar and ductal cells highlighted the potential involvement of TYMP in regulating the pathological process of ADM. Klf4 was identified as an upstream transcription factor regulating the Tymp gene. ATAC-seq revealed increased chromatin accessibility at the Klf4 and Tymp locus under inflammatory injury or oncogenic Kras conditions. Dual-luciferase reporter assays demonstrated that the transcription factor Klf4 binds to the promoter region of Tymp, thereby promoting its transcriptional expression. Pancreatic overexpression of Klf4 in mice upregulated Tymp expression and facilitated inflammation-induced initiation and progression of ADM. Exogenous supplementation with Tipiracil Hydrochloride suppressed the effects induced by Klf4. Knockdown of the Tymp gene suppressed inflammation-driven initiation and progression of ADM in KC mice through Pi3k/Akt and Mek/Erk pathways.
Conclusions: The Klf4-Tymp axis promotes inflammation-associated early pancreatic tumorigenesis by enhancing KRAS mutation-induced ADM through activation of the Pi3k/Akt and Mek/Erk signaling pathways. These findings provide new insights into the molecular mechanisms linking inflammatory injury to ADM and early pancreatic tumorigenesis.
期刊介绍:
The Journal of Experimental & Clinical Cancer Research is an esteemed peer-reviewed publication that focuses on cancer research, encompassing everything from fundamental discoveries to practical applications.
We welcome submissions that showcase groundbreaking advancements in the field of cancer research, especially those that bridge the gap between laboratory findings and clinical implementation. Our goal is to foster a deeper understanding of cancer, improve prevention and detection strategies, facilitate accurate diagnosis, and enhance treatment options.
We are particularly interested in manuscripts that shed light on the mechanisms behind the development and progression of cancer, including metastasis. Additionally, we encourage submissions that explore molecular alterations or biomarkers that can help predict the efficacy of different treatments or identify drug resistance. Translational research related to targeted therapies, personalized medicine, tumor immunotherapy, and innovative approaches applicable to clinical investigations are also of great interest to us.
We provide a platform for the dissemination of large-scale molecular characterizations of human tumors and encourage researchers to share their insights, discoveries, and methodologies with the wider scientific community.
By publishing high-quality research articles, reviews, and commentaries, the Journal of Experimental & Clinical Cancer Research strives to contribute to the continuous improvement of cancer care and make a meaningful impact on patients' lives.